Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2014 | Research

Neogenin expression is inversely associated with breast cancer grade in ex vivo

Authors: Wanying Xing, Qiang Li, Rangjuan Cao, Zheli Xu

Published in: World Journal of Surgical Oncology | Issue 1/2014

Abstract

Background

Neogenin is closely related to the human tumor suppressor gene deleted in colorectal cancer and plays a role in mammary morphogenesis. This study aimed to assess neogenin expression in breast cancer for any clinically significant association.

Methods

A total of 54 breast cancer patients who underwent modified radical mastectomy were enrolled for immunohistochemical and quantitative real-time PCR analysis of neogenin expression in their cancerous breast tissues in comparison to matching distant non-cancerous tissues.

Results

The data showed that the neogenin protein was either strongly or moderately expressed in the cytoplasm of the distant non-cancerous cells. In contrast, neogenin protein was either weakly or not expressed in the cytoplasm of 51/54 (94.4%) breast cancer cells, among which 13 breast cancer cases did not express neogenin protein at all (13/54, 24.1%). Similarly, levels of neogenin mRNA were significantly lower in breast cancer tissues than that of the matched distant non-cancerous tissues (51/54, 94.4%). Neogenin expression was inversely associated with breast cancer grade; that is, grade III breast cancer expressed much less neogenin than grade I-II (P < 0.05).

Conclusions

This study indicates that neogenin expression in breast cancer tissues is inversely associated with tumor grade.

Available only for authorised users

Dey S, Soliman AS: Cancer in the global health era: opportunities for the Middle East and Asia. Asia Pac J Public Health. 2010, 22: 75S-82S. 10.1177/1010539510372846.CrossRefPubMed

Wang YC, Wei LJ, Liu JT, Li SX, Wang QS: Comparison of cancer incidence between China and the USA. Cancer Biol Med. 2012, 9: 128-132.PubMedCentralPubMed

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRefPubMed

La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F: Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010, 21: 1323-1360. 10.1093/annonc/mdp530.CrossRefPubMed

Chung C, Christianson M: Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract. 2014, 20: 11-28. 10.1177/1078155212474047.CrossRefPubMed

Pathmanathan N, Balleine RL: Ki67 and proliferation in breast cancer. J Clin Pathol. 2013, 66: 512-516. 10.1136/jclinpath-2012-201085.CrossRefPubMed

Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17: 1474-1481.PubMed

Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, To TV, Qian Z, Love RR, Allred DC: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004, 17: 1545-1554. 10.1038/modpathol.3800229.CrossRefPubMed

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010, 28: 509-518. 10.1200/JCO.2009.23.1274.CrossRefPubMed

10.

Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L: Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn. 2004, 4: 169-188. 10.1586/14737159.4.2.169.CrossRefPubMed

11.

Allred DC: Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer. Modern Pathology. 2010, 23: S52-S59.CrossRefPubMed

12.

Stagg J, Allard B: Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013, 5: 169-181. 10.1177/1758834012475152.PubMedCentralCrossRefPubMed

13.

Meyerhardt JA, Look AT, Bigner SH, Fearon ER: Identification and characterization of neogenin, a DCC-related gene. Oncogene. 1997, 14: 1129-1136. 10.1038/sj.onc.1200935.CrossRefPubMed

14.

Rajagopalan S, Deitinghoff L, Davis D, Conrad S, Skutella T, Chedotal A, Mueller BK, Strittmatter SM: Neogenin mediates the action of repulsive guidance molecule. Nat Cell Biol. 2004, 6: 756-762. 10.1038/ncb1156.CrossRefPubMed

15.

Matsunaga E, Tauszig-Delamasure S, Monnier PP, Mueller BK, Strittmatter SM, Mehlen P, Chédotal A: RGM and its receptor neogenin regulate neuronal survival. Nat Cell Biol. 2004, 6: 749-755. 10.1038/ncb1157.CrossRefPubMed

16.

De Vries M, Cooper HM: Emerging roles for neogenin and its ligands in CNS development. J Neurochem. 2008, 106: 1483-1492. 10.1111/j.1471-4159.2008.05485.x.CrossRefPubMed

17.

Hebrok M, Reichardt LF: Brain meets pancreas: netrin, an axon guidance molecule, controls epithelial cell migration. Trends Cell Biol. 2004, 14: 153-155. 10.1016/j.tcb.2004.02.005.PubMedCentralCrossRefPubMed

18.

Liu Y, Stein E, Oliver T, Li Y, Brunken WJ, Koch M, Tessier-Lavigne M, Hogan BLM: Novel role for netrins in regulating epithelial behavior during lung branching morphogenesis. Curr Biol. 2004, 14: 897-905. 10.1016/j.cub.2004.05.020.PubMedCentralCrossRefPubMed

19.

Lu X, Le Noble F, Yuan L, Jiang Q, De Lafarge B, Sugiyama D, Bréant C, Claes F, De Smet F, Thomas J-L: The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature. 2004, 432: 179-186. 10.1038/nature03080.CrossRefPubMed

20.

Arakawa H: Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer. 2004, 4: 978-987. 10.1038/nrc1504.CrossRefPubMed

21.

Fitamant J, Guenebeaud C, Coissieux M-M, Guix C, Treilleux I, Scoazec J-Y, Bachelot T, Bernet A, Mehlen P: Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. PNAS. 2008, 105: 4850-4855. 10.1073/pnas.0709810105.PubMedCentralCrossRefPubMed

22.

Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan P, Moore KJ, Kinane TB: Netrin-1 inhibits leukocyte migration in vitro and in vivo. Science Signaling. 2005, 102: 14729-

23.

Lee JE, Kim HJ, Bae JY, Kim SW, Park J-S, Shin HJ, Han W, Kim S-W, Kang K-S, Noh D-Y: Neogenin expression may be inversely correlated to the tumorigenicity of human breast cancer. BMC Cancer. 2005, 5: 154-10.1186/1471-2407-5-154.PubMedCentralCrossRefPubMed

24.

Benson JR, Weaver DL, Mittra I, Hayashi M: The TNM staging system and breast cancer. Lancet Oncol. 2003, 4: 56-60. 10.1016/S1470-2045(03)00961-6.CrossRefPubMed

25.

Frank GA, Danilova NV, Andreeva I, Nefedova NA: [WHO classification of tumors of the breast, 2012]. Arkh Patol. 2013, 75: 53-63.PubMed

26.

Wu X, Li Y, Wan X, Kayira TM, Cao R, Ju X, Zhu X, Zhao G: Down-regulation of neogenin accelerated glioma progression through promoter methylation and its overexpression in SHG-44 induced apoptosis. PLoS One. 2012, 7: e38074-10.1371/journal.pone.0038074.PubMedCentralCrossRefPubMed

27.

Li VS, Yuen ST, Chan TL, Yan HH, Law WL, Yeung BH, Chan AS, Tsui WY, So S, Chen X, Leung SY: Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. Gastroenterology. 2009, 137: 176-187. 10.1053/j.gastro.2009.03.005.CrossRefPubMed

28.

Latil A, Chene L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P, Cussenot O: Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer. 2003, 103: 306-315. 10.1002/ijc.10821.CrossRefPubMed

29.

Bondy ML, Scheurer ME, Malmer B, Barnholtz‒Sloan JS, Davis FG, Il'Yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA: Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008, 113: 1953-1968. 10.1002/cncr.23741.PubMedCentralCrossRefPubMed

30.

Lavelle K, Moran A, Howell A, Bundred N, Campbell M, Todd C: Older women with operable breast cancer are less likely to have surgery. Br J Surg. 2007, 94: 1209-1215. 10.1002/bjs.5834.CrossRefPubMed

31.

Bernet A, Mehlen P: Dependence receptors: when apoptosis controls tumor progression. Bull Cancer. 2007, 94: 10012-10017.

32.

Strizzi L, Bianco C, Raafat A, Abdallah W, Chang C, Raafat D, Hirota M, Hamada S, Sun Y, Normanno N, Callahan R, Hinck L, Salomon D: Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. J Cell Sci. 2005, 118 (Pt 20): 4633-43.CrossRefPubMed

Title: Neogenin expression is inversely associated with breast cancer grade in ex vivo
Authors: Wanying Xing
Qiang Li
Rangjuan Cao
Zheli Xu
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-12-352

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neogenin expression is inversely associated with breast cancer grade in ex vivo

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Reliable management of post-esophagectomy anastomotic fistula with endoscopic trans-fistula negative pressure drainage

A mixture of carcinoid tumors, extensive neuroendocrine proliferation, and multiple pulmonary sclerosing hemangiomas

MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma

CD40 mutant expression and its clinical significance to prognosis in gastric cancer patients

A case report of retroperitoneal pararenal Castleman’s disease associated with myasthenia gravis

The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer